Special Issue

Rapid Antifungal Susceptibility Testing and Diagnostics of Antifungal Resistance

Message from the Guest Editor

Invasive fungal infections remain an underrecognized health problem, compounded by diagnostic challenges and the growing emergence of resistance to the limited antifungal agents currently available. Epidemiological data indicate a worldwide rise in severe mycosis, with over 150 million cases and an estimated 1.7 million deaths annually. Emerging species such as *Nakaseomyces glabratus*, *Pichia kudriavzevii*, and *Candida auris*, have become increasingly important pathogens due to their intrinsic and acquired resistance to antifungal agents. In particular, *C. auris* is a multidrug-resistant pathogen that poses a significant global threat to human health. Developing improved diagnostic tools and targeted antifungal strategies is critical to preserving drug effectiveness. This Special Issue focuses on antimicrobial resistance, including antifungal resistance. Topics of interest include the development of new antifungal drugs, advances in understanding resistance mechanisms, novel in vitro susceptibility data, and innovative strategies to combat fungal infections. Together, these contributions aim to advance the knowledge necessary to address antifungal resistance effectively.

Guest Editor

Dr. Valentina Salas
Laboratorio Referencia Micología Médica, Instituto de Salud Pública de Chile, Santiago, Chile

Deadline for manuscript submissions

31 October 2026

Antibiotics

an Open Access Journal by MDPI

Impact Factor 5.5
CiteScore 10.2
Indexed in PubMed

mdpi.com/si/253516

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 5.5
CiteScore 10.2
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI